Publication:
Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma

0
0

Issued Date

2019

Resource Type

Article

File Type

application/pdf

ISSN

2780232

DOI

10.1002/hon.2687

Other identifier(s)

2-s2.0-85075039642

Rights Holder(s)

Scopus

Bibliographic Citation

Hematological Oncology. Vol 37, No.5 (2019), p.578-585

Suggested Citation

Wudhikarn K., Bunworasate U., Julamanee J., Lekhakula A., Ekwattanakit S., Khuhapinant A., Niparuck P., Chuncharunee S., Numbenjapon T., Prayongratana K., Kanitsap N., Wongkhantee S., Makruasri N., Wong P., Norasetthada L., Nawarawong W., Sirijerachai C., Chansung K., Suwanban T., Praditsuktavorn P., Intragumtornchai T., On Behalf Of Thai Lymphoma Study Group Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Hematological Oncology. Vol 37, No.5 (2019), p.578-585. doi:10.1002/hon.2687 Retrieved from: https://hdl.handle.net/20.500.14740/5078

Title

Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma

Author(s)

Wudhikarn K.
 Bunworasate U.
 Julamanee J.
 Lekhakula A.
 Ekwattanakit S.
 Khuhapinant A.
 Niparuck P.
 Chuncharunee S.
 Numbenjapon T.
 Prayongratana K.
 Kanitsap N.
 Wongkhantee S.
 Makruasri N.
 Wong P.
 Norasetthada L.
 Nawarawong W.
 Sirijerachai C.
 Chansung K.
 Suwanban T.
 Praditsuktavorn P.
 Intragumtornchai T.
 On Behalf Of Thai Lymphoma Study Group

Abstract

Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker for peripheral T cell lymphoma (PTCL). We reviewed 293 systemic PTCL patients at 13 nationwide major university hospitals in Thailand from 2007 to 2014. The median event free survival (EFS) and overall survival (OS) of PTCL patients in our cohort was 16.3 and 27.7 months with corresponding 2-year EFS and 2-year OS of 45.8% and 51.9%, respectively. A total of 118 patients achieved EFS24 (no events during the first 24 mo). Patients who achieved EFS24 had better OS than patients who did not (2-y OS 92% vs 18.8%; HR, 0.1; P <.001). The standardized mortality ratio of patients achieving EFS24 was 18.7 (95% CI, 14.6-22.8). Multivariable analysis demonstrated performance status, histologic subtype, remission status, and EFS24 achievement as independent predictors for OS. Our study affirmed the value of EFS24 as a powerful prognostic factor for PTCL. Further validation in prospective study setting is warranted. ©2019 John Wiley & Sons, Ltd.

Subject(s)

Cyclophosphamide
 Cyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus vincristine
 Dexamethasone
 Doxorubicin
 Lactate dehydrogenase
 Prednisolone
 Tumor marker
 Vincristine
 Antineoplastic agent
 Advanced cancer
 Aged
 Article
 Blood toxicity
 Cancer combination chemotherapy
 Cancer mortality
 Cancer prognosis
 Cancer regression
 Cancer survival
 Controlled study
 Disease severity
 Drug dose reduction
 Event free survival
 Febrile neutropenia
 Female
 Human
 Major clinical study
 Male
 Overall survival
 Peripheral T cell lymphoma
 Priority journal
 Standardized mortality ratio
 Systemic disease
 Thailand
 Therapy delay
 Adult
 Disease free survival
 Health survey
 Kaplan Meier method
 Middle aged
 Mortality
 Peripheral T cell lymphoma
 Prognosis
 Treatment outcome
 Adult
 Antineoplastic Combined Chemotherapy Protocols
 Disease-Free Survival
 Female
 Humans
 Kaplan-Meier Estimate
 Lymphoma, T-Cell, Peripheral
 Male
 Middle Aged
 Prognosis
 Progression-Free Survival
 Public Health Surveillance
 Thailand
 Treatment Outcome

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/5078

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By